Trial Profile
Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)/ Covid-19
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Apremilast (Primary) ; Eritoran (Primary) ; Hydroxychloroquine (Primary) ; Interferon beta-1a (Primary) ; Lopinavir/ritonavir (Primary) ; Mercaptamine (Primary) ; Sarilumab (Primary) ; Tocilizumab (Primary) ; TRV 027 (Primary) ; Amoxicillin/clavulanic acid; Ascorbic acid; Aspirin; Azithromycin; Azithromycin; Baloxavir-marboxil; Baricitinib; Ceftaroline fosamil; Ceftriaxone; Clarithromycin; Clarithromycin; Clopidogrel; Convalescent anti-SARS-CoV-2 plasma; Dalteparin sodium; Dalteparin sodium; Dexamethasone; Dexamethasone; Erythromycin; Heparin; Hydrocortisone; Interferon beta-1; Levofloxacin; Lopinavir; Lopinavir; Low molecular weight heparins; Macrolides; Moxifloxacin; Oseltamivir; Piperacillin/tazobactam; Plasma; Prasugrel; Ritonavir; Roxithromycin; Simvastatin; Ticagrelor; Vitamins
- Indications Community-acquired pneumonia; COVID 2019 infections; COVID-19 pneumonia; Influenza virus infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms AD-SCAP; REMAP-CAP; REMAP-COVID
- 25 Oct 2023 Results published in the New England Journal of Medicine
- 12 Sep 2023 Planned number of patients changed from 10000 to 20000.
- 01 Jun 2023 Planned End Date changed from 1 Dec 2025 to 1 Feb 2028.